Agios Total Other Income Expense Net vs Ebit Analysis

AGIO Stock

USD 55.54 0.92 1.68%

Agios Pharm financial indicator trend analysis is way more than just evaluating Agios Pharm prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Agios Pharm is a good investment. Please check the relationship between Agios Pharm Total Other Income Expense Net and its Ebit accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.

Total Other Income Expense Net vs Ebit

Total Other Income Expense Net vs Ebit Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Agios Pharm Total Other Income Expense Net account and Ebit. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Agios Pharm's Total Other Income Expense Net and Ebit is -0.49. Overlapping area represents the amount of variation of Total Other Income Expense Net that can explain the historical movement of Ebit in the same time period over historical financial statements of Agios Pharm, assuming nothing else is changed. The correlation between historical values of Agios Pharm's Total Other Income Expense Net and Ebit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Other Income Expense Net of Agios Pharm are associated (or correlated) with its Ebit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebit has no effect on the direction of Total Other Income Expense Net i.e., Agios Pharm's Total Other Income Expense Net and Ebit go up and down completely randomly.

Correlation Coefficient

-0.49

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Total Other Income Expense Net

Ebit

Most indicators from Agios Pharm's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Agios Pharm current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.At this time, Agios Pharm's Sales General And Administrative To Revenue is very stable compared to the past year. As of the 22nd of November 2024, Enterprise Value is likely to grow to about 1.5 B, while Selling General Administrative is likely to drop about 81.2 M.

	2021	2022	2023	2024 (projected)
Interest Expense	836K	12.8M	14.7M	15.4M
Depreciation And Amortization	18.8M	18.6M	6.6M	8.3M

Interest Expense Depreciation And Amortization

Agios Pharm fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock
Total Assets		0.7	0.51	0.97	-0.13	0.81	-0.09	0.03	-0.47	0.71	0.12	0.92	-0.15	0.45	0.98	0.89	0.88	0.98	0.26	0.83	0.84	0.33	0.6	0.98	0.02	0.9
Other Current Liab	0.7		0.88	0.52	0.44	0.79	0.18	-0.21	-0.9	0.85	0.37	0.65	-0.38	0.1	0.65	0.79	0.91	0.67	0.73	0.72	0.93	0.81	0.52	0.69	0.28	0.81
Total Current Liabilities	0.51	0.88		0.33	0.51	0.5	0.48	-0.42	-0.83	0.85	0.53	0.47	-0.33	-0.09	0.46	0.63	0.76	0.51	0.65	0.46	0.79	0.77	0.34	0.5	0.56	0.65
Total Stockholder Equity	0.97	0.52	0.33		-0.37	0.7	-0.17	0.06	-0.27	0.59	0.07	0.89	-0.1	0.49	0.96	0.83	0.76	0.96	0.0	0.72	0.71	0.07	0.53	0.95	-0.07	0.84
Other Liab	-0.13	0.44	0.51	-0.37		0.09	0.48	-0.32	-0.48	0.22	0.35	-0.15	0.05	-0.4	-0.13	-0.04	0.18	-0.19	0.84	0.17	0.19	0.82	-0.02	-0.12	0.47	-0.03
Property Plant And Equipment Net	0.81	0.79	0.5	0.7	0.09		-0.33	0.35	-0.7	0.62	-0.19	0.77	-0.49	0.36	0.71	0.8	0.86	0.76	0.56	0.88	0.86	0.58	0.61	0.79	-0.21	0.82
Current Deferred Revenue	-0.09	0.18	0.48	-0.17	0.48	-0.33		-0.8	-0.02	0.36	0.78	-0.15	0.16	-0.3	-0.02	-0.05	-0.04	-0.07	0.17	-0.29	-0.03	0.24	-0.29	-0.06	0.96	-0.04
Net Debt	0.03	-0.21	-0.42	0.06	-0.32	0.35	-0.8		0.05	-0.35	-0.99	0.04	-0.24	0.41	-0.08	0.02	-0.05	0.01	0.0	0.26	-0.04	-0.09	0.31	0.02	-0.71	0.0
Retained Earnings	-0.47	-0.9	-0.83	-0.27	-0.48	-0.7	-0.02	0.05		-0.67	-0.18	-0.46	0.45	-0.02	-0.37	-0.66	-0.8	-0.45	-0.76	-0.61	-0.86	-0.82	-0.52	-0.44	-0.12	-0.68
Accounts Payable	0.71	0.85	0.85	0.59	0.22	0.62	0.36	-0.35	-0.67		0.48	0.74	-0.35	0.04	0.67	0.74	0.81	0.66	0.45	0.52	0.81	0.56	0.37	0.65	0.41	0.78
Cash	0.12	0.37	0.53	0.07	0.35	-0.19	0.78	-0.99	-0.18	0.48		0.1	0.17	-0.34	0.22	0.13	0.21	0.13	0.1	-0.11	0.2	0.19	-0.21	0.12	0.71	0.15
Non Current Assets Total	0.92	0.65	0.47	0.89	-0.15	0.77	-0.15	0.04	-0.46	0.74	0.1		-0.26	0.29	0.89	0.78	0.81	0.83	0.23	0.73	0.79	0.29	0.49	0.83	-0.1	0.82
Non Currrent Assets Other	-0.15	-0.38	-0.33	-0.1	0.05	-0.49	0.16	-0.24	0.45	-0.35	0.17	-0.26		0.14	0.01	-0.23	-0.27	-0.12	-0.18	-0.07	-0.38	-0.22	0.09	-0.09	0.17	-0.24
Other Assets	0.45	0.1	-0.09	0.49	-0.4	0.36	-0.3	0.41	-0.02	0.04	-0.34	0.29	0.14		0.46	0.36	0.29	0.47	-0.06	0.43	0.23	-0.07	0.7	0.5	-0.09	0.34
Cash And Short Term Investments	0.98	0.65	0.46	0.96	-0.13	0.71	-0.02	-0.08	-0.37	0.67	0.22	0.89	0.01	0.46		0.84	0.82	0.95	0.21	0.8	0.76	0.27	0.57	0.97	0.1	0.85
Common Stock Total Equity	0.89	0.79	0.63	0.83	-0.04	0.8	-0.05	0.02	-0.66	0.74	0.13	0.78	-0.23	0.36	0.84		0.89	0.92	0.32	0.78	0.91	0.41	0.67	0.9	0.07	1.0
Common Stock Shares Outstanding	0.88	0.91	0.76	0.76	0.18	0.86	-0.04	-0.05	-0.8	0.81	0.21	0.81	-0.27	0.29	0.82	0.89		0.86	0.55	0.86	0.98	0.63	0.64	0.86	0.07	0.9
Short Term Investments	0.98	0.67	0.51	0.96	-0.19	0.76	-0.07	0.01	-0.45	0.66	0.13	0.83	-0.12	0.47	0.95	0.92	0.86		0.18	0.78	0.83	0.26	0.6	0.99	0.06	0.92
Non Current Liabilities Total	0.26	0.73	0.65	0.0	0.84	0.56	0.17	0.0	-0.76	0.45	0.1	0.23	-0.18	-0.06	0.21	0.32	0.55	0.18		0.57	0.55	0.99	0.37	0.26	0.26	0.35
Other Current Assets	0.83	0.72	0.46	0.72	0.17	0.88	-0.29	0.26	-0.61	0.52	-0.11	0.73	-0.07	0.43	0.8	0.78	0.86	0.78	0.57		0.81	0.58	0.76	0.83	-0.13	0.78
Other Stockholder Equity	0.84	0.93	0.79	0.71	0.19	0.86	-0.03	-0.04	-0.86	0.81	0.2	0.79	-0.38	0.23	0.76	0.91	0.98	0.83	0.55	0.81		0.64	0.62	0.81	0.07	0.92
Total Liab	0.33	0.81	0.77	0.07	0.82	0.58	0.24	-0.09	-0.82	0.56	0.19	0.29	-0.22	-0.07	0.27	0.41	0.63	0.26	0.99	0.58	0.64		0.39	0.32	0.34	0.43
Property Plant And Equipment Gross	0.6	0.52	0.34	0.53	-0.02	0.61	-0.29	0.31	-0.52	0.37	-0.21	0.49	0.09	0.7	0.57	0.67	0.64	0.6	0.37	0.76	0.62	0.39		0.62	-0.07	0.66
Total Current Assets	0.98	0.69	0.5	0.95	-0.12	0.79	-0.06	0.02	-0.44	0.65	0.12	0.83	-0.09	0.5	0.97	0.9	0.86	0.99	0.26	0.83	0.81	0.32	0.62		0.08	0.89
Short Term Debt	0.02	0.28	0.56	-0.07	0.47	-0.21	0.96	-0.71	-0.12	0.41	0.71	-0.1	0.17	-0.09	0.1	0.07	0.07	0.06	0.26	-0.13	0.07	0.34	-0.07	0.08		0.07
Common Stock	0.9	0.81	0.65	0.84	-0.03	0.82	-0.04	0.0	-0.68	0.78	0.15	0.82	-0.24	0.34	0.85	1.0	0.9	0.92	0.35	0.78	0.92	0.43	0.66	0.89	0.07

Click cells to compare fundamentals

Agios Pharm Account Relationship Matchups

Agios Pharm fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	890.7M	853.0M	1.4B	1.2B	937.1M	752.6M
Other Current Liab	53.1M	61.9M	32.0M	30.4M	28.2M	28.5M
Total Current Liabilities	92.9M	94.4M	59.8M	62.6M	68.0M	75.2M
Total Stockholder Equity	640.5M	399.5M	1.3B	1.1B	811.0M	564.7M
Other Liab	77.4M	50.6M	261.3M	3.3M	3.8M	3.6M
Property Plant And Equipment Net	126.1M	117.5M	104.2M	88.1M	69.8M	52.5M
Net Debt	32.7M	(22.2M)	(106.0M)	(53.6M)	(16.2M)	(17.0M)
Retained Earnings	(1.5B)	(1.8B)	(238.8M)	(470.6M)	(822.6M)	(863.8M)
Accounts Payable	21.9M	17.7M	16.7M	18.6M	9.8M	15.1M
Cash	80.9M	127.4M	203.1M	139.3M	88.2M	83.8M
Non Current Assets Total	279.0M	216.3M	373.5M	405.9M	103.3M	178.4M
Non Currrent Assets Other	(279.0M)	1.1M	2.9M	4.0M	4.1M	4.3M
Cash And Short Term Investments	564.9M	670.5M	1.3B	1.1B	776.9M	637.5M
Common Stock Total Equity	58K	68K	69K	71K	81.7K	49.5K
Common Stock Shares Outstanding	60.0M	69.0M	60.4M	54.8M	55.7M	48.8M
Short Term Investments	483.9M	445.5M	816.9M	643.9M	688.7M	428.3M
Liabilities And Stockholders Equity	890.7M	853.0M	1.4B	1.2B	937.1M	752.6M
Non Current Liabilities Total	157.3M	359.1M	85.9M	75.3M	58.1M	112.7M
Other Current Assets	24.2M	49.1M	39.8M	39.0M	35.0M	22.1M
Other Stockholder Equity	2.2B	2.2B	1.5B	1.6B	1.6B	1.2B
Total Liab	250.2M	453.5M	145.8M	137.9M	126.1M	187.9M
Property Plant And Equipment Gross	31.5M	117.5M	28.9M	138.2M	122.0M	128.1M
Total Current Assets	611.7M	636.7M	1.1B	832.8M	833.8M	574.2M
Accumulated Other Comprehensive Income	202K	105K	(1.2M)	(12.5M)	(441K)	(463.1K)
Short Term Debt	6.9M	14.8M	11.2M	13.7M	30.0M	39.8M
Common Stock	58K	68K	69K	71K	72K	51.8K
Property Plant Equipment	31.5M	32.3M	28.9M	23.0M	26.4M	21.1M
Net Tangible Assets	640.5M	399.5M	1.3B	1.1B	1.3B	633.1M
Net Receivables	15.3M	25.4M	4.4M	2.2M	2.8M	2.7M
Retained Earnings Total Equity	(1.5B)	(1.8B)	(238.8M)	(470.6M)	(423.5M)	(444.7M)
Capital Surpluse	2.2B	2.2B	2.3B	2.4B	2.7B	1.7B
Inventory	7.3M	14.7M	16.2M	8.5M	19.1M	20.0M
Long Term Investments	152.9M	97.6M	266.4M	313.9M	29.4M	28.0M
Non Current Liabilities Other	157.3M	359.1M	85.9M	3.3M	1.2M	1.1M
Net Invested Capital	640.5M	399.5M	1.3B	1.1B	811.0M	833.9M
Net Working Capital	518.8M	542.3M	1.0B	770.1M	765.9M	702.8M

Pair Trading with Agios Pharm

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agios Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharm will appreciate offsetting losses from the drop in the long position's value.

Moving against Agios Stock

0.85	TCHH	Trustcash Holdings	Pair Corr
0.76	PFE	Pfizer Inc Fiscal Year End 4th of February 2025	Pair Corr
0.7	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.61	ME	23Andme Holding	Pair Corr
0.6	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr

The ability to find closely correlated positions to Agios Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agios Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agios Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agios Pharm to buy it.

The correlation of Agios Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agios Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agios Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Agios Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Agios Pharm offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Agios Pharm's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Agios Pharm Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Agios Pharm Stock:

How To Invest In Agios

Details

Is Agios Stock a good investment?

Details

What is Agios Pharm's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.

You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

11.66

Revenue Per Share

0.582

Quarterly Revenue Growth

0.212

Return On Assets

(0.18)

Return On Equity

0.5366

The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Agios Total Other Income Expense Net vs Ebit Analysis

Total Other Income Expense Net vs Ebit

Total Other Income Expense Net vs Ebit Correlation Analysis

Correlation Coefficient

Total Other Income Expense Net

Ebit

Agios Pharm fundamental ratios Correlations

Agios Pharm Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Agios Pharm fundamental ratios Accounts

Pair Trading with Agios Pharm

Moving against Agios Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Total Equity
Total Current Assets	+ 0.99	Short Term Investments
Total Liab	+ 0.99	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.98	Total Assets
Short Term Investments	+ 0.98	Total Assets
Total Current Assets	+ 0.98	Total Assets

Cash	- 0.99	Net Debt
Retained Earnings	- 0.9	Other Current Liab
Other Stockholder Equity	- 0.86	Retained Earnings
Retained Earnings	- 0.83	Total Current Liabilities
Total Liab	- 0.82	Retained Earnings
Common Stock Shares Outstanding	- 0.8	Retained Earnings